Sydney, Sept 5, 2008 (ABN Newswire) - Neuren Pharmaceuticals (ASX:NEU)(PINK:NURPF) announced that the Company has been informed that an additional US$5.5 million in funding will be made available by the US Army for the Company’s planned Phase II clinical trial of NNZ-2566 in traumatic brain injury (TBI). With the previously announced grant of US$4 million to cover direct costs of the study, this results in a total commitment of approximately US$10 million.
